Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1636
This examiner grants 63% of resolved cases
Kyle Thomas Rega is an examiner in Tech Center 1600 and Art Unit 1636. He has 118 resolved cases in his record. The allowance rate for these cases is 62.7 percent. This 62.7 percent rate provides a baseline for applicants to understand the frequency of patent grants in his docket. With 118 resolved cases, the data offers a perspective on his examination history.
The interview lift is 41.4 percent. This 41.4 percent figure shows the increase in the likelihood of allowance when an interview is conducted compared to the overall allowance rate. Practitioners in Art Unit 1636 can use this lift to inform their strategy. The median days to allowance is 1292. This 1292-day period represents the time typically required to reach a grant. Stakeholders can use the 1292-day metric and the 62.7 percent allowance rate to plan their prosecution timelines in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18332335 | Polynucleotides, Compositions, and Methods for Genome Editing Involving Deamination | Non-Final OA | Intellia Therapeutics, Inc. |
| 18490880 | TRANSCRIPTIONAL PROGRAMMING IN A BACTEROIDES CONSORTIUM | Final Rejection | Georgia Tech Research Corporation |
| 17324383 | METHODS AND SYSTEMS FOR DETECTION OF KIDNEY DISEASE OR DISORDER BY GENE EXPRESSION ANALYSIS | Non-Final OA | The Regents of the University of California |
| 17770531 | A CRISPR-CAS9 PLATFORM WITH AN INTRINSIC OFF-SWITCH AND ENHANCED SPECIFICITY | Final Rejection | The Johns Hopkins University |
| 18544882 | METHODS FOR THE IDENTIFICATION OF VARIANT RECOGNITION SITES FOR RARE-CUTTING ENGINEERED DOUBLE-STRAND-BREAK-INDUCING AGENTS AND COMPOSITIONS AND USES THEREOF | Final Rejection | PIONEER HI-BRED INTERNATIONAL, INC. |
| 17084721 | TYPE V CRISPR-CAS BASE EDITORS AND METHODS OF USE THEREOF | Final Rejection | Pairwise Plants Services, Inc. |
| 16984885 | COMPOSITIONS AND METHODS FOR IDENTIFYING A SINGLE-NUCLEOTIDE VARIANT | Final Rejection | President and Fellows of Harvard College |
| 17552431 | ENGINEERED SSDNASE-FREE CRISPR ENDONUCLEASES | Final Rejection | MONSANTO TECHNOLOGY LLC |
| 17612245 | NON-CLASS I MULTI-COMPONENT NUCLEIC ACID TARGETING SYSTEMS | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18282421 | Compositions and Methods for the Treatment of Conditions Associated with Nucleotide Repeat Expansion | Non-Final OA | The General Hospital Corporation |
| 18287677 | PRODUCTS AND METHODS FOR TREATING MUSCULAR DYSTROPHY | Final Rejection | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 17632263 | EXON 44-TARGETED NUCLEIC ACIDS AND RECOMBINANT ADENO-ASSOCIATED VIRUS COMPRISING SAID NUCLEIC ACIDS FOR TREATMENT OF DYSTROPHIN-BASED MYOPATHIES | Final Rejection | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 18594869 | CRISPR TRANSIENT EXPRESSION CONSTRUCT (CTEC) | Non-Final OA | DSM IP ASSETS B.V. |
| 18043792 | SYSTEMS AND METHODS FOR CONTROLLING BACTERIAL TRANSCRIPTION | Final Rejection | UNIVERSITY OF UTAH RESEARCH FOUNDATION |
| 17290317 | Split CPF1 Protein | Non-Final OA | The University of Tokyo |
| 18053696 | METABOLIC ENGINEERING OF CUPRIAVIDUS NECATOR FOR IMPROVED FORMATE UTILIZATION | Final Rejection | Alliance for Energy Innovation, LLC |
| 16616655 | ALTERED GUIDE RNAS FOR MODULATING CAS9 ACTIVITY AND METHODS OF USE | Final Rejection | North Carolina State University |
| 17709903 | PLURIPOTENT STEM CELL, NERVE CELL, AND APPLICATION THEREOF | Final Rejection | KEIO UNIVERSITY |
| 17636750 | COMPOSITIONS AND METHODS FOR IDENTIFYING REGULATORS OF CELL TYPE FATE SPECIFICATION | Non-Final OA | Duke University |
| 17272005 | SCALABLE TAGGING OF ENDOGENOUS GENES BY HOMOLOGY-INDEPENDENT INTRON TARGETING | Final Rejection | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy